A Study of Rizatriptan Co-Administered With Acetaminophen for the Treatment of Acute Migraine
NCT ID: NCT00300924
Last Updated: 2008-05-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
200 participants
INTERVENTIONAL
2006-03-31
2007-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Rizatriptan co-administered with Acetaminophen
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has at least a 6 month history of migraine, with or without aura
* Subject can distinguish between migraine attacks and other types of headaches
* Subject of childbearing potential agrees to use adequate contraception
Exclusion Criteria
* Subject typically has greater than 10 headache days per month
* Subject has evidence of ischemic heart disease
* Subject has uncontrolled high blood pressure
* Subject has a history, within 1 year, or current evidence of drug or alcohol abuse
\*This list is not all inclusive\*
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Diamond Headache Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Diamond Headache Clinic
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Merle Diamond, M.D.
Role: STUDY_DIRECTOR
Diamond Headache Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
SanFrancisco Headache Clinic
San Francisco, California, United States
Diamond Headache Clinic
Chicago, Illinois, United States
Westside Family Medical Center
Kalamazoo, Michigan, United States
Clinvest
Springfield, Missouri, United States
Mercy Health Research
St Louis, Missouri, United States
Elkind Headache Center
Mount Vernon, New York, United States
ClinExcel
West Chester, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Merk 075-00
Identifier Type: -
Identifier Source: secondary_id
Merck 075-00
Identifier Type: -
Identifier Source: org_study_id